- Home
- ADPT vs NPWR Comparison
ADPT vs NPWR Comparison
Compare ADPT & NPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- NPWR
- Stock Information
- Founded
- ADPT 2009
- NPWR 2010
- Country
- ADPT United States
- NPWR United States
- Employees
- ADPT 709
- NPWR N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- NPWR Industrial Machinery/Components
- Sector
- ADPT Health Care
- NPWR Energy
- Exchange
- ADPT Nasdaq
- NPWR Nasdaq
- Market Cap
- ADPT 749.7M
- NPWR 665.3M
- IPO Year
- ADPT 2019
- NPWR N/A
- Fundamental
- Price
- ADPT $5.08
- NPWR $12.67
- Analyst Decision
- ADPT Buy
- NPWR Hold
- Analyst Count
- ADPT 4
- NPWR 2
- Target Price
- ADPT $6.50
- NPWR $9.50
- AVG Volume (30 Days)
- ADPT 1.1M
- NPWR 754.9K
- Earning Date
- ADPT 11-07-2024
- NPWR 11-11-2024
- Dividend Yield
- ADPT N/A
- NPWR N/A
- EPS Growth
- ADPT N/A
- NPWR N/A
- EPS
- ADPT N/A
- NPWR 0.11
- Revenue
- ADPT $177,282,000.00
- NPWR $250,000.00
- Revenue This Year
- ADPT $3.82
- NPWR N/A
- Revenue Next Year
- ADPT $20.38
- NPWR $7,463.34
- P/E Ratio
- ADPT N/A
- NPWR $119.91
- Revenue Growth
- ADPT N/A
- NPWR 38.12
- 52 Week Low
- ADPT $2.28
- NPWR $6.57
- 52 Week High
- ADPT $6.70
- NPWR $14.28
- Technical
- Relative Strength Index (RSI)
- ADPT 47.04
- NPWR 75.83
- Support Level
- ADPT $5.09
- NPWR $8.63
- Resistance Level
- ADPT $6.70
- NPWR $14.28
- Average True Range (ATR)
- ADPT 0.46
- NPWR 0.92
- MACD
- ADPT 0.00
- NPWR 0.40
- Stochastic Oscillator
- ADPT 24.48
- NPWR 72.60
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system which it refers to as the "NET Power Cycle is designed to produce clean, reliable and low-cost electricity from natural gas while capturing virtually all atmospheric emissions.